EASL 2013 Report – Probiotics reduces hepatic encephalopathy in cirrhotic patients
Probiotics have significantly reduced development of hepatic encephalopathy researchers announced at EASL/International Liver Congress.
Probiotics have significantly reduced development of hepatic encephalopathy researchers announced at EASL/International Liver Congress.
Hepatitis C patients treated with Merck’s investigative MK-5172, an oral NS3/4A protease inhibitor, combined with 24 or 48 weeks of peginterferon alfa 2b (Pegasys/ Roche) and ribavirin (Ribasphere/… read more.
Researchers reported encouraging but preliminary results of gene-based immune therapy in two children with relapsed and refractory acute lymphoblastic leukemia (ALL).
Researchers have found that macrophages that play a key role in the immune response – also help to both produce and eliminate the body’s red blood cells (RBCs)…. read more.
Patients at Manchester Royal Infirmary are playing a vital role in an international trial to find out if a blood test can accurately confirm a heart attack within… read more.
A new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC –… read more.
Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Haematology (ASH) signal an important step forward… read more.
Studies of stem cell biology and transplant approaches presented at the 54th Annual Meeting of the American Society of Haematology (ASH) illustrate how the use of advanced modelling… read more.
New research, presented at the 54th Annual Meeting of the American Society of Haematology (ASH), has identified important associations between Plasmodium falciparum (Pf) malaria and endemic Burkitt Lymphoma (eBL) that… read more.
by Sung Choi, M.D., University of Michigan Comprehensive Cancer Center (pictured) First study in humans shows promise for preventing graft-versus-host disease following bone marrow transplant.
The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic… read more.
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3… read more.